top of page

On a mission to develop safe and effective treatments for our pet family members

Therapeutic Areas

Molecule_edited.jpg

ATOPIC DERMATITIS

A chronic severe skin condition that leads to itching for millions of dogs and cats

Ankle%20and%20Ligaments_edited.jpg

OSTEOARTHRITIS

Chronic joint pain that results in lameness for millions of horses and dogs

Recent News

4/2/2022

Data read out for the pilot study for ALX 101 at North Carolina State University demonstrates both efficacy of the product and a positive consumer experience

1/25/2021

First patient in the pilot study for ALX 101 at North Carolina State University enrolled.

5/28/2020

Aniluxx Biotechnology is invited to participate in MassChallenge Houston

3/25/2020

FDA accepts the INAD submission for ALX 101, an investigational topical therapy for canine allergic dermatitis

1/16/2020  

Aniluxx to Present at the North Carolina Biotechnology Center Symposium on Itch

1/08/2020

Aniluxx selected to Present at the North Carolina Center for Entrepreneurial Development Life Sciences Conference

12/20/2019

Aniluxx Files SEC Form D Reporting Seed Stage Investment

Thanks for submitting!

bottom of page